RNF5 and primary effusion lymphoma: Collectively, these findings highlight the crucial role of RNF5 in both KSHV lytic replication and PEL tumorigenesis, suggesting the exciting possibility of utilizing RNF5 inhibition as a strategy for treating KSHV infection and PEL.